SEARCH

SEARCH BY CITATION

References

  • 1
    Grady D, Gebretsadik J, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 1995; 85: 304313.
  • 2
    Sturdee DW, Wade-Evans T, Paterson MEL, Thom M, Studd JWW. Relations between bleeding pattern, endometrial biopsy and oestrogen treatment in menopausal women. BMJ 1978; 1: 15751577.
  • 3
    Pike MC, Peters RK, Cozen W et al. Estrogen-progestin replacement therapy and endometrial cancer. J Natl Cancer Inst 1997; 89: 11101116.
  • 4
    Woodruff JD, Pickar JH, for the Menopause Study Group. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone. Am J Obstet Gynecol 1994; 170: 12131223.
  • 5
    The Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. JAMA 1996; 275: 370375.
  • 6
    Sturdee DW, Barlow DH, Ulrich LG et al. Is the timing of withdrawal bleeding a guide to endometrial safety during sequential oestrogen-progestagen replacement therapy Lancet 1994; 344: 979982.
  • 7
    Persson I, Adami HO, Bergkvist L et al. Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study. BMJ 1989; 298: 147151.
  • 8
    Voigt LF, Weiss NS, Chu J, Daling JR, McKnight B, van Belle G. Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer. Lancet 1991; 338: 274277.
  • 9
    Persson I, Yuen J, Bergkvist L, Schairer C. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy: long-term follow-up of a Swedish cohort. Int J Cancer 1996; 67: 327332.
  • 10
    Beresford SAA, Weiss NS, Voigt LF, McKnight B. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 1997; 349: 458461.
  • 11
    Weiderpass E, Adami HO, Baron JA et al. Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 1999; 91: 11311137.
  • 12
    Barentsen R, Groeneveld FP, Bareman FP, Hoes AW, Dokter HJ, Drogendijk AC. Women's opinion on withdrawal bleeding with hormone replacement therapy. Eur J Obstet Gynecol Reprod Biol 1993; 51: 203207.
  • 13
    Hahn RG. Compliance considerations with estrogen replacement: withdrawal bleeding and other factors. Am J Obstet Gynecol 1989; 161: 18541858.
  • 14
    Ravnikar VA. Barriers for taking long-term hormone replacement therapy: why do women not adhere to therapy Eur Menopause J 1996; 3 (Suppl 2): 9093.
  • 15
    Rees M. On menstrual bleeding with hormone replacement therapy. Lancet 1994; 343: 250.
  • 16
    Obel EB, Munk-Jensen N, Svenstrup B et al. A two-year, double-blind controlled study of the clinical effect of combined and sequential postmenopausal replacement therapy and steroid metabolism during treatment. Maturitas 1993; 16: 1321.
  • 17
    Mattsson L-Å, Cullberg G, Samsioe G. Evaluation of a continuous oestrogen-progestogen regimen for climacteric complaints. Maturitas 1982; 4: 95102.
  • 18
    Sporrong T, Hellgren M, Samsioe G, Mattsson L-Å. Comparison of four continuously administered progestogens plus estradiol combinations for climacteric complaints. Br J Obstet Gynaecol 1988; 95: 10421048.
  • 19
    Staland B. Continuous treatment with a combination of estrogen and gestagen: a way of avoiding endometrial stimulation. Clinical experiences with Kliogest. Acta Obstet Gynaecol Scand 1985; (Suppl 130): 2935.
  • 20
    Hawthorn RJS, Spowart K, Walsh D, McKay Hart D. The endometrial status of women on long-term continuous combined hormone replacement therapy. Br J Obstet Gynaecol 1991; 98: 939942.
  • 21
    Staland B. Continuous treatment with natural oestrogens and progestagens. A method to avoid endometrial stimulation. Maturitas 1981; 3: 145156.
  • 22
    Archer DF, Pickar JH, Bottiglioni F. Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate. Menopause Study Group. Obstet Gynecol 1994; 83: 686692.
  • 23
    Pickar JH, Archer DF, for the Menopause Study Group (United States, Italy, Netherlands, Switzerland, Belgium, Germany, and Finland). Is bleeding a predictor of endometrial hyperplasia in postmenopausal women receiving hormone replacement therapy Am J Obstet Gynecol 1997; 177: 11781183.
  • 24
    Shapiro S, Kelly JP, Rosenberg L et al. Risk of localized and widespread endometrial cancer in relation to recent and discontinued use of conjugated estrogens. N Engl J Med 1985; 313: 969972.
  • 25
    Paganini-Hill A, Ross RK, Henderson BE. Endometrial cancer and patterns of use of estrogen replacement therapy: a cohort study. Br J Cancer 1989; 59: 445447.
  • 26
    Norris HJ, Connor MP, Kurman RJ. Preinvasive lesions of the endometrium. Clin Obstet Gynaecol 1986; 13: 725738.
  • 27
    Kurman RJ. The behavior of endometrial hyperplasia. A long-term study of ‘untreateD’ hyperplasia in 170 patients. Cancer 1985; 56: 403412.
  • 28
    Jick SS. Combined estrogen and progesterone use and endometrial cancer. Epidemiology 1993; 4: 384.
  • 29
    Paterson MEL, Wade-Evans T, Sturdee DW, Thom MH, Studd JWW. Endometrial disease after treatment with oestrogens and progestogens in the climacteric. BMJ 1980; 280: 822824.
  • 30
    Whitehead MI. The effects of oestrogens and progestogens on the postmenopausal endometrium. Maturitas 1978; 1: 8798.
  • 31
    Schiff I, Sela HK, Cramer D, Tilchinsky D, Ryan KJ. Endometrial hyperplasia in women on cyclic or continuous estrogen regimens. Fertil Steril 1982; 27: 7982.
  • 32
    Varma TR. Effect of long-term therapy with estrogen and progesterone on the endometrium of postmenopausal women. Acta Obstet Gynecol Scand 1985; 64: 4146.
  • 33
    Fox H. Endometrial hyperplasia; a conceptual and practical approach. Eur Menopause J 1995; 2: 1012.
  • 34
    Thom MH, White PJ, Williams RM et al. Prevention and treatment of endometrial disease in climacteric women receiving oestrogen therapy. Lancet 1979; 2: 455457.
  • 35
    Ferenczy A, Gelfand M. The biologic significance of cytologic atypia in progestogen-treated endometrial hyperplasia. Am J Obstet Gynecol 1989; 160: 126131.
  • 36
    Padwick ML, Pryse-Davies J, Whitehead MI. A simple method for determining the optimal dose of progestin in postmenopausal women receiving estrogens. N Engl J Med 1986; 315: 930934.
  • 37
    McGonigle KF, Karlan BY, Barbuto DA, Leuchter RS, Lagasse LD, Judd HL. Development of endometrial cancer in women on estrogen and progestin hormone replacement therapy. Gynecol Oncol 1994; 55: 126132.
  • 38
    Mant JWF, Vessey MP. Ovarian and endometrial cancers. In: DollR, FraumeniJFJr, MuirCS, editors. Cancer Surveys: Trends in Cancer Incidence and Mortality, Volume 19. Plainview , New York : Cold Spring Harbor Laboratory Press, 1994: 287307.
  • 39
    Ravnikar VA. Compliance with hormone replacement therapy. Am J Obstet Gynecol 1987; 156: 13321334.
  • 40
    Barlow DH, Grosset KA, Hart H, Hart DM. A study of the experience of Glasgow women in the climacteric years. Br J Obstet Gynaecol 1989; 96: 11921197.
  • 41
    Guner H, Tiras MB, Karabacak O, Sarikaya H, Erdem M, Yildirim M. Endometrial assessment by vaginal ultrasonography might reduce endometrial sampling in patients with postmenopausal bleeding: a prospective study. Aust N Z J Obstet Gynaecol 1996; 36: 175178.
  • 42
    Mortakis AE, Mavrelos K. Transvaginal ultrasonography and hysteroscopy in the diagnosis of endometrial abnormalities. J Am Assoc Gynecol Laparosc 1997; 4: 449452.
  • 43
    Lindgren R, Mattsson L-Å, Andersson K et al. Transvaginal ultrasonography and endometrial histology in peri- and postmenopausal women on hormone replacement therapy. Br J Obstet Gynaecol 1999; 106: 421426.
  • 44
    Udoff L, Langenberg P, Adashi EY. Combined continuous hormone replacement therapy: a critical review. Obstet Gynecol 1995; 86: 306316.
  • 45
    Stadberg E, Mattsson LÅ, Uvebrant M. 17 beta-estradiol and norethisterone acetate in low doses as continuous combined hormone replacement therapy. Maturitas 1996; 23: 3139.
  • 46
    Nand SL, Webster MA, Baber R, O'Connor V, for the Ogen/Provera Study Group. Bleeding pattern and endometrial changes during continuous combined hormone replacement therapy. Obstet Gynecol 1998; 91: 678684.
  • 47
    Leather AT, Savvas M, Studd JW. Endometrial histology and bleeding patterns after 8 years of continuous combined oestrogen and progestogen therapy in postmenopausal women. Obstet Gynecol 1991; 78: 10081010.
  • 48
    McGonigle KF, Karlan BY, Barbuto DA, Leuchter RS, Lagasse LD, Judd HL. Development of endometrial cancer in women on estrogen and progestin hormone replacement therapy. Gynecol Oncol 1994; 55: 126132.
  • 49
    Comerci JT, Fields AL, Runowicz CD, Goldberg GL. Continuous low-dose combined hormone replacement therapy and the risk of endometrial cancer. Gynecol Oncol 1997; 64: 425430.
  • 50
    Weinstein L, Bewtra C, Gallagher C. Evaluation of a continuous combined low-dose regimen of estrogen-progestin for treatment of the menopausal patient. Am J Obstet Gynecol 1990; 162: 15341542.
  • 51
    Spowart KJM, Walsh DJ, Hawthorn RJS, Hart D. Hysteroscopic assessment of the effects of a continuous combined oestrogen-progestagen regimen on the endometrium of postmenopausal women. Gynaecol Endosc 1992; 1: 3335.
  • 52
    Hillard TC, Siddle NC, Whitehead MI. Continuous combined conjugated equine estrogen-progestagen therapy: effects of medroxyprogesterone acetate and norethindrone acetate on bleeding patterns and endometrial histologic diagnosis. Am J Obstet Gynecol 1992; 167: 1017.
  • 53
    Piegsa K, Calder A, Davis JA, McKay Hart D, Wells M, Bryden F. Endometrial status in post-menopausal women on long-term continuous combined hormone replacement therapy (Kliofem) a comparative study of endometrial biopsy, outpatient hysteroscopy and transvaginal ultrasound. Eur J Obstet Gynecol Reprod Biol 1997; 72: 175180.